Platelets have been implicated in colon cancer metastasis and prognosis but the underlying molecular mechanisms remain unclear. We evaluated the role of the different mitogen-activated protein kinase (MAPK) pathways in platelet-stimulated matrix metalloproteinase-9 (MMP-9) generation and colon cancer invasion. In addition, proteins released during platelet-tumour cell interactions were studied. For this purpose, interactions of Caco-2 and HT29 cells with platelets were studied using scanning electron microscopy, aggregometry, flow cytometry and cell invasion chambers. Quantitative PCR and zymography were used to study MMP-9 gene expression and activity, respectively, whereas western blot was used to study p38MAPK. Finally, the origin of proteins during platelet-cancer cell interactions was investigated using stable isotope labelling by amino acids in cell culture (SILAC)-based proteomics. We found that platelets promoted p38MAPK phosphorylation and MMP-9 up-regulation in both cell lines, with the subsequent cell-invasion-promoting effects. Pharmacological inhibition of p38MAPK led to a significant down-regulation of MMP-9 and colon cancer cell invasiveness. Also, p38MAPK-small interfering RNA abolished the induction of platelet-stimulated MMP-9. SILAC experiments demonstrated that thrombospondin 1 (TSP1) was released mainly from platelets and clusterin by both platelets and cancer cells. Finally, inhibition of TSP1 and clusterin abolished p38MAPK phosphorylation, MMP-9 activity and platelet-stimulated colon cancer invasion. Our results indicate that platelet-secreted TSP1 and clusterin promote the signal regulation of MMP-9 in platelet-induced colonic cancer invasion via a P38MAPK-regulated pathway. These findings are relevant to the development of therapeutic approaches to preventing and reducing tumour cell metastasis induced by colon adenocarcinoma.
Introduction
Approximately 40-50% of newly diagnosed patients with colorectal cancer develop metastatic disease (1) . Accumulating evidence suggests that tumour progression is governed not only by genetic changes intrinsic to cancer cells (2) but also by epigenetic and environmental factors. It has been known for over a century that the interactions between tumour cells and platelets are crucial for the haematogenous spread of cancer (3) . Indeed, thrombocytosis and platelet activation have been previously reported in patients suffering from colon cancer and is associated with poor survival (4) (5) (6) . In addition, experimental evidence has shown that platelets have the capacity to contribute to different stages of cancer progression including angiogenesis, invasion, survival in circulation and metastasis (7) (8) (9) (10) .
Metastasis and invasion of tumour cells require various processes including the loss of cell adhesion, degradation of the extracellular matrix (ECM) and concomitant induction of cell movement. The ECM remodelling is an active event during tumour progression. On the one hand, ECM serves as a niche for tumour cells to survive and proliferate. On the other, it is a barrier that suppresses the spreading of tumour cells (11, 12) . Various proteases, including matrix metalloproteinases (MMPs) released from tumour cells are involved in the breakdown of ECM proteins. MMPs are enzymes that play a main role in cancer evolution and they have been extensively implicated as crucial factors in tumour cell migration and invasion (13, 14) . Among the MMPs, the gelatinase MMP-9 seems to play a key role in colonic cancer progression (15) and metastasis (16) . In light of these findings, MMPs were considered as ideal drug targets. However, so far, the use of MMP inhibitors in cancer therapy has suffered significant set-backs (17, 18) . Hence, insights into the signalling mechanisms involved in MMP-9 up-regulation in cancer invasion could provide opportunities for developing new therapeutic approaches.
Gene transcription is the rate-limiting step in MMP-9 regulation. The MMP-9 gene is transcriptionally responsive to several factors, including cytokines, growth factors and cell-cell and cell-ECM interactions (19) . The mitogen-activated protein kinases (MAPKs) are proline-directed serine/threonine kinases, which are activated via dual phosphorylation in response to extracellular stimuli (20) . The MAPK family includes extracellular signal-regulated kinase (ERK), p38 and c-Jun NH(2)-terminal kinase (JNK). MAPKs are major signal transduction molecules that are involved in regulating a variety of cellular responses, including proliferation, differentiation, survival and apoptosis. In cancer, MAPKs have been shown to contribute to proliferation, migration and invasion (20) . There is increasing evidence for an important role for the p38MAPK pathway in promoting cancer cell growth, survival and invasion (21) .
We hypothesized that MAPKs, in particular the p38MAPK pathway, could be involved in the signalling regulation of MMP-9 in platelet-induced colon cancer invasion. We found that platelets indeed stimulate colon cancer invasiveness by enhancing MMP-9 activity and expression via the p38MAPK pathway, an effect which was mediated in part by platelet-secreted proteins such as clusterin and thrombospondin 1 (TSP1).
Materials and methods

Tumour cell culture
Two human colon cancer cell lines, Caco-2 and HT29 adenocarcinoma cells, were obtained from the European Cell Culture Collection. Cell lines were cultured as monolayers in 75 ml culture flasks at 37°C in a humidified atmosphere with 5% CO 2 . Caco-2 and HT29 cells were cultured in minimum essential medium (MEM) supplemented with 10% fetal bovine serum and gentamicin (0.05 mg/ml), penicillin (0.06 mg/ml) and streptomycin (0.01 mg/ml). The cells were supplied with fresh medium and subcultured three times each week.
Preparation of human washed platelets
Blood was collected from healthy volunteers who had not taken any drugs known to affect platelet function for at least 14 days prior to the study. Washed platelet (WP) suspensions (2.5 × 10 8 platelets/ml) were prepared as described before (22) . For tumour cell-platelet interactions, cell invasion and co-incubation studies, platelets were resuspended in serum-free MEM.
P38MAPK-mediated invasion in colon cancer
Light aggregometry and flow cytometry
The interactions between platelets and tumour cells were measured by light aggregometry and flow cytometry. Briefly, WP samples (2.5 × 10 8 /ml) were placed in an eight channel PAP 8 aggregometer (Bio/Data Corporation, Horsham, PA) and incubated for 10 min at 37°C, with stirring at 900 r.p.m., prior to the addition of aggregating agents (collagen 2 µg/ml or cancer cells). Following addition of aggregating agents, aggregation was measured for at least 30 min using Aggro-Link software.
The abundance of P-selectin on the surface of platelets was measured by flow cytometry. Platelet samples were first activated with either Caco-2 or HT29 cells. When platelet aggregation reached 50% maximal light transmission, the reaction was terminated by 10-fold dilution with physiological concentration of saline. Resting platelets were used as control. Platelet samples were then incubated in the dark without stirring for 5 min at room temperature in the presence of saturating concentrations (10 µg/ml) of P-selectin (CD62P-APC). Following incubation, samples were diluted in fluorescence-activated cell sorting (FACS) Flow fluid and analysed within 5 min using a BD FACSArray (BD Biosciences, Oxford, UK). Flow cytometry was performed on single stained platelet samples. Fluorescence histograms were obtained for 10 000 individual events. Data were analysed using BD FACSArray software.
Scanning electron microscopy
For the scanning electron microscopy (SEM) imaging, Caco-2 and HT29 cells were incubated with WP for 2 h. Afterwards, samples were rinsed twice with phosphate-buffered saline, fixed using 2.5% glutaraldehyde for 30 min at 37°C and then dehydrated through ascending grades of ethanol (60% for 20 min, 80% for 20 min, 90% for 20 min and finally 100% for 30 min repeated once). Thereafter, samples were mounted on aluminium stubs and coated with gold/ palladium (10 nm coating); the formation of platelet aggregates on the tumour cells was then visualized using a Zeiss Ultra Plus Field Emission Scanning Electron Microscope (Germany) at 3.00 kV.
Tumour cell-platelet co-incubation experiments
Platelet suspensions in serum-free MEM (2.5 × 10 8 platelets/ml) were added to T25-cell culture flasks containing subconfluent Caco-2 and HT29 cells. Platelets were allowed to interact with tumour cells for 24 h in the presence or absence of inhibitors. Platelets and tumour cells are known to produce MMPs, however, only cancer cells have the ability to synthesize de novo proteins. Therefore, we used two different inhibitors of de novo protein synthesis, cycloheximide (35 µM) and actinomycin D (0.8 µM) to study the cellular source of these MMPs in colon cancer cell-platelet interactions. Furthermore, three different inhibitors of MAPKs were used to characterize the MAPKdependent pathway of platelet-induced MMP-9 expression by Caco-2 and HT29 cells: PD98059 (20 µM), a selective inhibitor for ERK; SP600125 (20 µM), a selective inhibitor for JNK and SB203580 (20 µM), a selective inhibitor for p38 pathway. Afterwards, conditioned media were collected and stored at −20°C for future determination of MMP activity as described below.
Cell survival
Flow cytometry was used to measure cell survival of tumour cells. Briefly, platelet suspensions in serum-free media (2.5 × 10 8 platelets/ml) were added to T25-cell culture flasks containing subconfluent Caco-2 and HT29 cells. Platelets were allowed to interact with tumour cells for up to 24 h in the presence or absence of the three MAPK inhibitors. Afterwards, cells were detached, pelleted and washed with 1× binding buffer (10 mm N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid/NaOH, pH 7.4, 140 mm NaCl, 2.5 mm CaCl 2 ). Finally, cells were incubated with annexin V-APC (5% vol/vol) and propidium iodide (5 µg/ml) in 1× binding buffer for 15 min in the dark at room temperature. Cells were further diluted with 1× binding buffer and analysed using a BD FACSArray (BD Biosciences). Ten thousand specific events were analysed.
Cell invasion assay
The BD BioCoat Matrigel Invasion Chamber assay system was used to study the effects of p38MAPK pathway inhibition on platelet-stimulated cancer cell invasion. The invasion assay was performed according to the manufacturer's instructions. Briefly, aliquots of 0.5 ml of cell suspensions consisting of 2.5 × 10 8 platelets/ml with 1 × 10 6 Caco-2 cells/ml and HT29 cells in the presence or absence of SB203580 (20 µM) and phenanthroline (1 µM) were added to the inserts and allowed to invade for 48 h in a humidified tissue culture incubator, at 37°C, 5% CO 2 atmosphere. The non-invading cells were afterwards removed by scrubbing with a cotton-tipped swab and the cells on the lower surface of the membrane were stained with Diff-Quik stain. The membrane was then examined by light microscopy using an Olympus CKX41 microscope (Olympus America, Melville, NY). All the experiments were carried out in triplicate. Further experiments were performed with anti-TSP1 and anticlusterin antibodies (Abcam, Cambridge, UK) as described previously (23, 24) .
Gelatin zymography
The conditioned media from the upper chambers of the invasion assays and the co-incubation experiments were removed and centrifuged, and the resulting cell-free supernatants were stored at −20°C until assayed for MMP-2 and MMP-9 using gelatin zymography (8, 25) . Briefly, gelatin zymography was performed using 8% sodium dodecyl sulphate-polyacrylamide gel electrophoresis with copolymerized gelatin (2 mg/ml). After electrophoresis, gels were washed in 2.5% Triton X-100 for 1 h (three times, 20 min each) and incubated for 24 h in enzyme assay buffer (25 mM Tris, pH 7.5, 5 mM CaCl 2 , 0.9% NaCl, 0.05% NaN 3 ). The gelatinolytic activities were detected as transparent bands against the background of Coomassie blue-stained gelatin.
Western blotting
Western blotting was used in order to investigate the p38MAPK pathway. Immunoblot analysis was performed as described previously (25) . Briefly, tumour cells and platelets were allowed to interact for 60 min. Afterwards, conditioned media were discarded and the attached cells were rinsed (phosphatebuffered saline ×3), detached and homogenized. Following electrophoresis, proteins were transferred onto nitrocellulose membrane (Protran; Schleicher & Schuell) and detected using a rabbit anti-phosphorylated p38MAPK antibody (Cell Signalling, UK). When appropriate, blots were stripped and analysed for β-actin (Sigma Chemical Co., UK) as an internal control and for total p38 (Cell Signalling). Further experiments were performed with a rabbit anti-TSP1 and a mouse anti-clusterin antibodies (Abcam).
Transfection experiments
Transient transfection of Caco-2 cells with 50 nM of three independent predesigned small interfering RNA (siRNA) and scrambled control siRNA (Applied Biosystems, UK), targeting p38MAPK pathway and designated siRNA 1213, siRNA 1217 and siRNA s3586 (Applied Biosystems), was performed by using Lipofectamine 2000 (Invitrogen, Ireland). Cells were seeded in six-well plate (2 × 10 5 cells per well) for these transfection studies.
After 48 h, the transfection mixture was removed and platelets were added for 24 h. Finally, cells were harvested for RNA extraction and western blotting.
Quantitative PCR
Quantitative PCR was used to demonstrate the role of p38MAPK in MMP-9 transcription in Caco-2 and HT29 cells. Platelet suspensions in serum-free MEM (2.5 × 10 8 platelets/ml) were added to T25-cell culture flasks containing subconfluent Caco-2 and HT29 cells and incubated during 24 h in the presence and absence of SB203580 (20 µM). Further experiments were performed with p38MAPK-siRNA. Briefly, total cellular RNA was isolated from cancer cells using RiboPure kit from Ambion (Austin, TX) according to manufacturer's protocol. For reverse transcription reaction, 1 µg of total RNA (High Capacity cDNA Archive Kit) was used and 10 ng of transcribed DNA was spent for each quantitative PCR reaction. As a target probe, TaqMan MGB human MMP-9 was used. Endogenous 18s rRNA was used as a control to normalize gene expression data, and an RQ value (2 −ΔΔCt , where Ct is the threshold cycle) was calculated for each sample. RQ values are presented as fold change in gene expression relative to the control group, which was normalized to 1.
Proteomics based on stable isotope labelling by amino acids in cell culture
Caco-2 cells were grown in stable isotope labelling by amino acids in cell culture (SILAC) media and Dulbecco's modified Eagle's medium R6K6 (Dundee Cell, UK) (where lysine and arginine were replaced with Lys 13 C6 and Arg 13 C6, respectively) with 20% dialyzed fetal bovine serum (Dundee Cell) for six generations to ensure that cells were fully labelled with the heavy-isotopeencoded amino acids. Afterwards, platelet suspensions in serum-free media (2.5 × 10 8 platelets/ml) were added to T75-cell culture flasks containing subconfluent Caco-2. Platelets were allowed to interact with tumour cells for 24 
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h. Caco-2 cells without platelets were also analysed. Following incubation, supernatants were collected and filtered by 0.45 µM Millipore filter and the Bradford protein assay was performed. Experiments were carried out on three different blood donors.
Liquid chromatography-tandem mass spectrometry analysis
Samples containing 10 mg of target protein were dried down in a Speedvac evaporator and resuspended in 50 µl of 8 M urea, 50 mM Tris-HCl (pH 8.0) and 4 mM dithiothreitol. The solution was heated at 60°C for 60 min. The samples were allowed to cool at room temperature and 350 µl of 50 mM NH 4 HCO 3 , 1 mM CaCl 2 (pH 7.8) was added to dilute the urea concentration to <1 M. Sequencing Grade Modified Trypsin from Promega (0.1 mg/ml in 50 mM acetic acid) was added in a ratio enzyme/protein of 1:50 (wt/wt) and the samples were incubated at 37°C overnight. Prior to mass spectrometry analysis, the samples were cleaned using ZipTips from Millipore and purified peptides dried down in a Speedvac concentrator.
Peptides were resuspended in 12 µl of 0.1% formic acid. Each sample was loaded onto a Biobasic C18 Picofrit TM column (100 mm length, 75 µm ID) and was separated by a 72 min reverse phase increasing acetonitrile gradient (0-50% acetonitrile for 50 min) at a flow rate of 30 nl/min on a Dionex Ultimate 3000 chromatography system incorporating an autosampler. Nanoelectrospray ionization liquid chromatography-tandem mass spectrometry was carried out on a Thermo Scientific LTQ ORBITRAP XL mass spectrometer.
The instrument was operated in positive ion mode with a capillary temperature of 200°C, a capillary voltage of 9 V, a tube lens voltage of 100 V and with a potential of 1800 V applied to the frit. All data was acquired with the mass spectrometer operating in automatic data dependent switching mode. A high resolution mass spectrometry scan (300-2000 Da) was performed using the Orbitrap, followed by tandem mass spectrometry analysis of the five most intense ions using the ion trap.
Raw data were converted into mgf peak lists using msconvert (ProteoWizard release 2.2.3181 (26)). Mgf files were searched using X!Tandem cyclone (27) (version 2011.05.01.1) through the global proteome machine interface against the ensemble human genome (GRCh37.64) and the common repository for adventitious proteins (cRAP) with the following search settings: tryptic cleavage with one miscleavage allowed, precursor error ±10 p.p.m., fragment ion error ±0.4 Da, carbamidomethylation as a fixed modification, separate searches were performed with Arg/Lys SILAC either set as a fixed modification (+ 6.02 Da@R,K) or not, Met oxidation was set as a variable modification. Searches were refined twice using deamidation on Asn and Gln; phosphorylation on Ser, Thr and Tyr; dioxidation on Trp and Met; methylation on Cys, Asp, Glu, His, Lys, Arg and Asn; carbamidomethylation on Lys, His, Asp and Glu as variable modifications. The peptide false positive rate (sum of all peptide expectation values for identified proteins) was <2% for all samples.
Statistics
Data were analysed using one-way analysis of variance (GraphPad Prism 3; GraphPad Software, San Diego, CA). Tukey-Kramer multiple comparisons test and paired and unpaired Student's t-tests were performed, where appropriate.
Results
Platelet-tumour cell interactions
At the beginning of each experiment, platelets were aggregated with low concentrations of collagen as internal standard of platelet reactivity. To study whether or not platelets were able to interact with tumour cells, aggregometry, flow cytometry and SEM studies were carried out. Supplementary Figure 1 , available at Carcinogenesis Online, shows tumour-cell-induced platelet aggregation and P-selectin translocation to the platelet membrane. Figure 1 illustrates SEM images of HT29 cell-platelet aggregates and Caco-2 cell-platelet aggregates, indicating that platelets become activated in the presence of tumour cells as they change their shape, extend pseudopodia and form platelet-tumour cell aggregates.
P38MAPK pathway in platelet-induced MMP-9 up-regulation
The production of several proteases including MMP-9 has been shown to be an essential step in tumour invasion and metastasis. Therefore, we first studied whether platelets were able to up-regulate MMP-9 in Caco-2 and HT29 cells. As shown in Figure 2 , platelets up-regulated MMP-9 at both protein and gene level. The requirement for de novo Normalized densitometric values of phosphorylated p38 MAPK (phospho p38) and total p38 MAPK (p38). Platelets induced a significant increase in phospho p38 (*P < 0.05 versus control). SB but not SP or PD down-regulated phospho p38 (#P < 0.05 versus wP). (C) Representative western blots of phosphorylated p38 MAPK (phospho p38) and total p38 MAPK (p38) in non-stimulated HT29 cells (c) and platelet-stimulated HT29 cells in the absence (wP) and presence of the three MAPK inhibitors (SP, PD, SB). (D) Normalized densitometric values of phosphorylated p38 MAPK (phospho p38) and total p38 MAPK (p38). Platelets induced a significant increase in phospho p38 (*P < 0.05 versus control). SB but not SP or PD down-regulated phospho p38 (#P < 0.05 versus wP).
MMP-9 protein synthesis in platelet-stimulated colon cancer cells was also shown by inhibiting both messenger RNA transcription and messenger RNA translation by actinomycin D and cycloheximide, respectively (Supplementary Figure 2 , available at Carcinogenesis Online). In addition, as MAPK proteins have been involved in tumour cell invasiveness, we investigated this pathway and its relationship to MMP-9 during tumour cell-platelet interactions. Treatment of platelet-stimulated HT29 and Caco-2 cells with SB203580, which is a selective inhibitor for p38 pathway, resulted in MMP-9 down-regulation (Figure 2) . In contrast, SP600125, a selective inhibitor for JNK, did not exert any significant effect (Figure 2 ). In addition, PD98059, a selective inhibitor for ERK, was able to reduce MMP-9 in Caco-2 cells, but not in HT29 cells (Figure 2) . These experiments, therefore, indicated that p38MAPK may control MMP-9 generation in both platelet-stimulated cell lines. Next, western blotting was performed to study if platelets could stimulate the phosphorylation of p38MAPK. Western blot analysis showed that platelets promote p38MAPK phosphorylation in both cell lines, an effect which was completely abolished by SB203580 (Figure 3) .
Finally, flow cytometry was carried out to study whether MAPK inhibitors exerted any effect on cell survival to rule out the possibility that MMP-9 down-regulation was due to cell death. From our studies, none of the MAPK inhibitors affected cell survival of either HT29 and Caco-2 cells at the relevant concentrations tested (Supplementary Figure 3 , available at Carcinogenesis Online).
P38MAPK-siRNA down-regulates MMP-9 in platelet-stimulated Caco-2 cells
To further confirm the involvement of p38MAPK pathway in MMP-9 regulation, colon cancer cells were transfected with p38-specific siRNA to induce transcript knockdown. We found that p38-deficient Caco-2 cells did not show p38 phosphorylation when incubated with platelets (wP; Figure 4A ). In addition, p38-deficient Caco-2 cells exhibited significant down-regulation of MMP-9 at gene level in the presence of platelets as shown in Figure 4B .
P38MAPK blockade down-regulates platelet-induced colon cancer invasion
Next, we studied the significance of p38MAPK-mediated MMP-9 expression for platelet-stimulated colon cancer invasion. Figure 5 shows that platelet-induced invasion of HT29 and Caco-2 cells was inhibited by the general MMP inhibitor phenanthroline and the p38MAPK inhibitor SB203580. The results of the invasion assay are consistent with the changes in MMP-9 activity ( Figure 5 ).
SILAC experiments
Knowing that platelets were able to phosphorylate p38MAPK and promote colon cancer cell invasiveness, we analysed proteins released during platelet-tumour cell interactions in order to identify platelet factors that may contribute to platelet-mediated cancer cell invasion. As platelets exerted a similar effect on both cell lines, these experiments were carried out on Caco-2 cells. We have already shown that media conditioned by cancer cells and platelets contain more secreted proteins than media conditioned by cancer cells alone (28) . However, our previous experiments did not show whether the secreted proteins were derived from the platelets or from the Caco-2 cells. Our proteomic experiments identified clusterin and TSP1 as major proteins secreted during platelet-tumour cell interactions that could potentially affect cancer cell invasiveness. Furthermore, in order to investigate the cellular source, we labelled Caco-2 cells with R6K6 media and co-incubated these cells with platelets. When the trypsin-digested media that were conditioned with Caco-2 cells with or without platelets were analysed by liquid chromatography-tandem mass spectrometry, peptides from proteins that were derived from the Caco-2 cells would be heavy labelled, whereas platelet-derived proteins would result in light peptides. We found that only light peptides are detected for TSP1 after co-incubation of heavy labelled Caco-2 cells with platelets. Interestingly, both heavy and light peptides were detected for clusterin after co-incubation of Caco-2 cells with platelets, providing evidence that this protein is secreted by both platelets and cells (Supplementary Figure 4 , available at Carcinogenesis Online). These results were corroborated by western blotting (Supplementary  Figure 4 , available at Carcinogenesis Online). A comprehensive list of proteins can be found in Supplementary Tables 1 and 2, available at Carcinogenesis Online.
Clusterin and TSP1 mediate p38MAPK phosphorylation and MMP-9 up-regulation in platelet-stimulated colon cancer cells
In order to investigate whether both clusterin and TSP1 were involved in p38 phosphorylation and MMP-9 up-regulation, Caco-2 cells were incubated in the presence or absence of anti-clusterin and anti-TSP1 antibodies. As shown in Figure 6 , both antibodies were able to downregulate p38 phosphorylation, MMP-9 activity and also platelet-stimulated colon cancer invasion.
Discussion
There is increasing evidence that platelet-tumour cell interactions support and promote the haematogenous dissemination of cancer cells to sites of distant metastasis. In this study, we provide pioneer evidence that a clusterin-and TSP1-dependent p38MAPK-MMP-9 pathway stimulates platelet-induced colon cancer invasion. First, we showed that both Caco-2 and HT29 cells were able to induce platelet activation and aggregation as evidenced by aggregometry, flow cytometry and SEM. Because platelets have the ability to up-regulate MMP-9 in breast cancer cells (10), we studied the expression and activity of MMP-9 in HT29 and Caco-2 cells. Indeed, we found that platelets dramatically increased MMP-9 in both cell lines. In addition, it was shown that de novo protein synthesis accounts for MMP-9 up-regulation as both cycloheximide and actinomycin D were able to reduce MMP-9 production in platelet-stimulated colon cancer cells. Moreover, the effect of platelets on MMP-9 secretion was specific for this gelatinase because MMP-2 expression was not affected. In fact, gene transcription of MMP-9 is inducible and the promoter region is highly responsive to growth factors and cytokines in several cells (19) . By contrast, MMP-2 is expressed constitutively by most cells and appears to be moderately induced or repressed (29) . However, the MT-1 MMP-MMP-2 system plays an important role in platelet aggregation via reciprocal interactions between platelets and tumour cells (7, 13, 30) . In addition, it has been found that the metastatic potential of tumour cells correlates with proteolytic degradation of basement membrane collagen mediated by MMPs (31) . Moreover, we have previously found that MMP-9 up-regulation is an early event in the colon adenoma-carcinoma sequence with a positive correlation between MMP-9 activity and the size of colonic polyps (15) . Taken together, these data suggest that MMP inhibitors could be a plausible strategic approach in colon cancer treatment. However, MMP inhibitors have failed to produce benefit in patients suffering from advanced cancer. Indeed, several Phase III Clinical Trials that evaluated the effectiveness of MMP inhibitors in advanced cancer have not demonstrated significant benefits for cancer patients. The main reasons for the clinical failure of MMP inhibitors seem to be the lack of selectivity as MMPs show multifaceted tumour-promoting and inhibiting actions as well as the use of inhibitors in advanced cancer. In addition, marimastat, a broad synthetic MMP inhibitor, was associated with systemic side effects (such as musculoskeletal pain and inflammation), which limited its use in subsequent clinical trials (17, 18) . Therefore, insights into the signalling mechanisms involved in MMP-9 up-regulation could be of utmost interest for the development of new therapeutic strategies.
Although it has been found that MMP-9 is dramatically increased when tumour cells are allowed to interact with platelets, the signalling pathways leading to MMPs production remain poorly understood. Interestingly, MMP-9 is controlled at gene level by different mediators, including MAPK family. Besides, MAPKs are critically involved in controlling multiple pathways in cancer cell invasiveness (32, 33) . Therefore, we used three different pharmacological MAPK inhibitors to investigate if MAPKs are involved in platelet-induced MMP-9 in colon cancer cells. It is difficult to explain the mechanism by which PD98059 (ERK inhibitor) only inhibited MMP-9 in Caco-2 cells. However, our results suggest that MMP-9 is regulated by cell-typespecific mechanisms due to presumably different genetic/epigenetic status in both cell lines (34) . We found that only SB203580 (p38MAPK inhibitor) was able to consistently down-regulate MMP-9 in both cell lines. These effects correlated well with the down-regulation of platelet-stimulated colon cancer cell invasion. Our findings are in agreement with previous studies, which showed that p38MAPK inhibition resulted in decreased MMP-9 activity in leukaemia and lung cancer cells (35, 36) . However, it is worth mentioning that this effect is most probably cell specific as it has been found that other MAPK pathways are also involved in the MMP-9 regulation in different cell lines (37, 38) . In addition, it has also been shown that p38MAPK activation is crucial for induction of the expression of other invasion-associated MMPs such as MMP-13 and MMP-1 in transformed keratinocytes (39) . However, a limitation of these results in the current study is that even selective pharmacological MAPK inhibitors may non-specifically inhibit other signalling pathways. Therefore, to address this concern, siRNA experiments were carried out. We found that p38-specific siRNA caused an inhibition in the expression and activity of MMP-9 in comparison with the negative control in Caco-2 cells. These results are in agreement with previous studies on 17-β-estradiol-treated LoVo colon cancer cells (40) . Therefore, taken together, our results clearly indicate that the p38MAPK pathway is involved in platelet-stimulated MMP-9 production and colon cancer invasion.
Knowing that platelets have the ability to phosphorylate p38MAPK and promote colon cancer invasion, we hypothesized that proteins released during cancer cell-platelet interactions may be involved in p38MAPK-stimulated induction of MMP-9. Indeed, we have recently shown that proteins such as RANTES and TSP1 released during tumour cell-platelet interactions could play an important role in cancer chemoresistance (28) . In addition, a number of platelet-secreted proteins are also known to promote cancer invasion and metastasis (38, 41, 42) . Therefore, we used SILAC experiments to study the secretome of proteins released during the interactions between platelets and colon cancer cells. Among the main proteins identified, clusterin and TSP1 are known to affect cell invasiveness. In fact, clusterin over-expression is a poor prognostic factor for patients suffering from colon cancer (43) . On the other hand, TSP1 may either stimulate or inhibit carcinogenesis. This glycoprotein may act as an anti-angiogenetic factor in colon cancer through different receptors (44) (45) (46) . However, TSP1 has been also implicated in cell adhesion, migration and invasion of solid tumours (47) . Our SILAC experiments revealed the cellular source of those proteins. TSP1 was released only by activated platelets, however clusterin was released by activated platelets and cancer cells as both light and heavy peptides for clusterin were found. Therefore, platelets have the capacity to promote the release of clusterin from tumour cells, and this underlines the importance of platelet-tumour cells interactions for the regulation of this glycoprotein during cancer growth and metastasis. Interestingly, under our experimental conditions, both anti-clusterin and TSP1 antibodies 
